Literature DB >> 27534388

Role of surgery in the management of anaplastic thyroid carcinoma: Korean nationwide multicenter study of 329 patients with anaplastic thyroid carcinoma, 2000 to 2012.

Seung-Kuk Baek1, Myung-Chul Lee2, J Hun Hah3, Soon-Hyun Ahn4, Young-Ik Son5, Young-Soo Rho6, Phil-Sang Chung7, Yoon-Se Lee8, Bon Seok Koo9, Kwang-Yoon Jung1, Byung-Joo Lee10.   

Abstract

BACKGROUND: The Korean Society of Thyroid Head and Neck Surgery established a nationwide multicenter registry of anaplastic thyroid carcinoma (ATC) and evaluated the prognostic factors and treatment outcomes of ATC.
METHODS: The present study enrolled 329 patients who were diagnosed with ATC between January 2000 and December 2012 at 19 medical centers in Korea. Survival outcomes were evaluated according to various clinical factors and treatments.
RESULTS: Multivariate analysis identified age ≥70 years old, the presence of initial clinical symptoms, distant metastasis, and treatment modality as significant risk factors (p <.05). The patients who underwent curative resection and adjuvant radiotherapy (RT) or concurrent chemoradiotherapy (CRT) showed the best survival on multivariate analysis (p < 0.05).
CONCLUSION: Although ATC is a lethal neoplasm, long-term survival may be acquired in cases in which the aggressive management, including curative resection or RT/concurrent CRT, is possible for therapeutic intent.
© 2016 Wiley Periodicals, Inc. Head Neck 39: 133-139, 2017. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  anaplastic thyroid carcinoma; multicenter study; multimodal treatment; prognostic factor; surgery

Mesh:

Year:  2016        PMID: 27534388     DOI: 10.1002/hed.24559

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  11 in total

1.  Multimodality Treatment Improves Locoregional Control, Progression-Free and Overall Survival in Patients with Anaplastic Thyroid Cancer: A Retrospective Cohort Study Comparing Oncological Outcomes and Morbidity between Multimodality Treatment and Limited Treatment.

Authors:  Pascal K C Jonker; John Turchini; Schelto Kruijff; Jia Feng Lin; Anthony J Gill; Thomas Eade; Ahmad Ahniss; Roderick Clifton-Bligh; Diana Learoyd; Bruce Robinson; Venessa Tsang; Anthony Glover; Stanley Sidhu; Mark Sywak
Journal:  Ann Surg Oncol       Date:  2021-05-25       Impact factor: 5.344

2.  Role of surgery to the primary tumor in metastatic anaplastic thyroid carcinoma: pooled analysis and SEER-based study.

Authors:  Dmytro Oliinyk; Teresa Augustin; Josefine Rauch; Viktoria Florentine Koehler; Claus Belka; Christine Spitzweg; Lukas Käsmann
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-12       Impact factor: 4.322

Review 3.  Airway management, symptom relief and best supportive care in anaplastic thyroid cancer.

Authors:  Kelly F Moyer; Andrea R Marcadis; Ashok R Shaha
Journal:  Curr Opin Otolaryngol Head Neck Surg       Date:  2020-04       Impact factor: 1.814

4.  Optimal combination of treatment modality to increase survival in patients with anaplastic thyroid carcinoma: A STROBE compliant retrospective study.

Authors:  Joon-Hyop Lee; Hee Kyung Ahn; Jae Yeon Seok; Kyu-Chan Lee; Yong Soon Chun; Yoo Seung Chung; Young Don Lee
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

5.  Treatment Outcomes in Anaplastic Thyroid Cancer.

Authors:  Kelsey L Corrigan; Hannah Williamson; Danielle Elliott Range; Donna Niedzwiecki; David M Brizel; Yvonne M Mowery
Journal:  J Thyroid Res       Date:  2019-05-23

6.  An Update of the Appropriate Treatment Strategies in Anaplastic Thyroid Cancer: A Population-Based Study of 735 Patients.

Authors:  Nai-Si Huang; Xiao Shi; Bo-Wen Lei; Wen-Jun Wei; Zhong-Wu Lu; Peng-Cheng Yu; Yu Wang; Qing-Hai Ji; Yu-Long Wang
Journal:  Int J Endocrinol       Date:  2019-02-19       Impact factor: 3.257

7.  Synergy of GSK-J4 With Doxorubicin in KRAS-Mutant Anaplastic Thyroid Cancer.

Authors:  Bo Lin; Bing Lu; I-Yun Hsieh; Zhen Liang; Zicheng Sun; Yang Yi; Weiming Lv; Wei Zhao; Jie Li
Journal:  Front Pharmacol       Date:  2020-05-13       Impact factor: 5.810

8.  2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer.

Authors:  Keith C Bible; Electron Kebebew; James Brierley; Juan P Brito; Maria E Cabanillas; Thomas J Clark; Antonio Di Cristofano; Robert Foote; Thomas Giordano; Jan Kasperbauer; Kate Newbold; Yuri E Nikiforov; Gregory Randolph; M Sara Rosenthal; Anna M Sawka; Manisha Shah; Ashok Shaha; Robert Smallridge; Carol K Wong-Clark
Journal:  Thyroid       Date:  2021-03       Impact factor: 6.568

9.  Evidence from an updated meta-analysis of the prognostic impacts of postoperative radiotherapy and chemotherapy in patients with anaplastic thyroid carcinoma.

Authors:  Quansong Xia; Wei Wang; Juan Xu; Xue Chen; Zhaoming Zhong; Chuanzheng Sun
Journal:  Onco Targets Ther       Date:  2018-04-19       Impact factor: 4.147

Review 10.  Uncommon Site of Metastasis and Prolonged Survival in Patients with Anaplastic Thyroid Carcinoma: A Systematic Review of the Literature.

Authors:  Aurora Mirabile; Matteo Biafora; Leone Giordano; Gianluigi Arrigoni; Maria Giulia Cangi; Italo Dell'Oca; Francesca Lira Luce; Davide Di Santo; Andrea Galli; Michele Tulli; Renata Mellone; Davide Valsecchi; Vanesa Gregorc; Mario Bussi
Journal:  Cancers (Basel)       Date:  2020-09-10       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.